Bristol-Myers Squibb ’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults with active Psoriatic Arthritis (PsA)1, a chronic2,...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news